...
首页> 外文期刊>In vivo. >Correlation of nm23-H1 gene expression with clinical outcome in patients with advanced breast cancer.
【24h】

Correlation of nm23-H1 gene expression with clinical outcome in patients with advanced breast cancer.

机译:晚期乳腺癌患者nm23-H1基因表达与临床结局的相关性。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Conflicting results exist regarding the significance of the metastasis suppressor gene nm23-H1 in cancer patients. Initial results from a study done by our group were more indicative of its negative prognostic role in breast cancer. Our aim was to examine further its significance in patients with metastatic breast cancer. PATIENTS AND METHODS: With the semi-quantitative Reverse Transcripted-Polymerase Chain Reaction (RT-PCR) method, solid tumor specimens or samples from malignant effusions in breast cancer patients were examined for the nm23-H1 gene. Clinical data were collected retrospectively and gene expression was correlated with survival. RESULTS: Fourteen patients were included in the current analysis. The gene was detected in 7 patients. No statistically significant differences were observed in the comparison done for prognostic factors between nm23-H1-positive and nm23-H1-negative patients. Women in whom the gene was not detected had longer median survival (49 vs. 6 months, p=0.09).CONCLUSION: In advanced breast cancer, nm23-H1, as detected by RT-PCR, seems to be a predictor of bad prognosis.
机译:背景:关于转移抑制基因nm23-H1在癌症患者中的意义存在矛盾的结果。我们小组进行的一项研究的初步结果更表明了其对乳腺癌的不良预后作用。我们的目的是进一步检查其在转移性乳腺癌患者中的意义。患者和方法:采用半定量逆转录聚合酶链反应(RT-PCR)方法,检查实体瘤标本或乳腺癌患者恶性积液样品中的nm23-H1基因。回顾性收集临床数据,并将基因表达与存活率相关。结果:本研究共纳入14例患者。在7例患者中检测到该基因。在nm23-H1阳性和nm23-H1阴性患者之间的预后因素比较中,未观察到统计学上的显着差异。未检测到该基因的女性中位生存期更长(49 vs. 6个月,p = 0.09)。结论:在晚期乳腺癌中,通过RT-PCR检测到nm23-H1似乎预示不良预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号